Alnylam Pharmaceuticals and Eli Lilly are competing in the biopharmaceutical market, with high trading volume driving market coverage by MarketBeat.

The entities involved

• Alnylam Pharmaceuticals →

  biopharmaceutical company

  • AstraZeneca's trial failure has created a competitive advantage for Alnylam Pharmaceuticals, which is leveraging AI in its commercial execution.Mon 11:04
  • Alnylam Pharmaceuticals, SEC, Truist Financial, and Nasdaq were involved in insider trading disclosures, analyst ratings, and stock trading on June 6, 2026.Sun 17:03
• Eli Lilly and Company →

  American pharmaceutical company

  • ExxonMobil, Berkshire Hathaway, and Eli Lilly are top holdings in the Avantis ETF.Mon 17:18
  • The FDA approved Olumiant for pediatric indications on September 1, 2026.Mon 05:59
• MarketBeat →

  American personal finance blog

  • Apple Inc. stock is traded on Nasdaq, and Jefferies Financial Group restated a hold rating on the company.Mon 17:22
  • MarketBeat aggregates data on IDT Corporation stock performance.Mon 17:15

Related events

• Market pressure due to cost trends is affecting major companies including UnitedHealth Group, Molina Healthcare, Abbott Laboratories, and Eli Lilly, as reported on Investopedia.Jun 8
• FDA approval clears the path for drug market entry, driving future regulatory focus for major pharmaceutical companies.Aug 18
• Morgan Stanley estimates market growth for GLP-1 drugs, noting competition between Eli Lilly and Novo Nordisk.Jun 8
• MarketBeat provided analyst ratings and targets for small-cap healthcare companies Emergent BioSolutions and Entrada Therapeutics.Sep 20
• MarketBeat aggregated analyst recommendations and price targets for BioMarin Pharmaceutical and Abeona Therapeutics Inc.Sep 4